These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 33930196)

  • 1. JAK inhibitors: Ten years after.
    Spinelli FR; Meylan F; O'Shea JJ; Gadina M
    Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
    Liu C; Kieltyka J; Fleischmann R; Gadina M; O'Shea JJ
    Arthritis Rheumatol; 2021 Dec; 73(12):2166-2178. PubMed ID: 34180156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
    Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibitors: Is specificity at all relevant?
    Gadina M
    Semin Arthritis Rheum; 2024 Feb; 64S():152327. PubMed ID: 38007359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
    Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
    Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
    Schwartz DM; Bonelli M; Gadina M; O'Shea JJ
    Nat Rev Rheumatol; 2016 Jan; 12(1):25-36. PubMed ID: 26633291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
    Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ
    Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK Inhibitors in Cytokine Storm Syndromes.
    Keenan C; Albeituni S; Nichols KE; Hines M
    Adv Exp Med Biol; 2024; 1448():583-600. PubMed ID: 39117841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
    T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
    BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
    Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
    Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Jakinibs in systemic lupus erythematosus: progress and prospects.
    Mok CC
    Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
    Zak M; Dengler HS; Rajapaksa NS
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK Inhibitors as a Barrier to the Destructive Cytokine Storm in COVID-19.
    Saeedi-Boroujeni A; Asadi-Samani M
    Curr Drug Res Rev; 2022; 14(2):85-87. PubMed ID: 35249523
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.
    Jain NK; Tailang M; Jain HK; Chandrasekaran B; Sahoo BM; Subramanian A; Thangavel N; Aldahish A; Chidambaram K; Alagusundaram M; Kumar S; Selvam P
    Front Pharmacol; 2023; 14():1135145. PubMed ID: 37021053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors for rheumatoid arthritis.
    Yamaoka K
    Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK-STAT inhibitors for the treatment of immunomediated diseases.
    Serra López-Matencio JM; Morell Baladrón A; Castañeda S
    Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK inhibitor selectivity: new opportunities, better drugs?
    Virtanen A; Spinelli FR; Telliez JB; O'Shea JJ; Silvennoinen O; Gadina M
    Nat Rev Rheumatol; 2024 Oct; 20(10):649-665. PubMed ID: 39251770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.